Prognosis and Immunotherapy Effect of Triple-Negative Breast Cancer by Lactylation-Related Genes and Experimental Validation
Yang Wang, Ying Xie, Yiyi Ye, Youyang Shi, Feifei Li, Mengdie Zhu, Ciyi Hua, Yuan Xu, Rui Yang, Sheng Liu · 2026
Read Prognosis and Immunotherapy Effect of Triple-Negative Breast Cancer by Lactylation-Related Genes and Experimental Validation by Yang Wang, Ying Xie, Yiyi Ye, Youyang Shi, Feifei Li, Mengdie Zhu, Ciyi Hua, Yuan Xu, Rui Yang, Sheng Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13292059.txt.
Description
Yang Wang and co-authors build a 2026 gene signature from lactylation-related genes to forecast outcomes and immunotherapy response in triple-negative breast cancer. Public tumor data were clustered by those genes, and a scoring model grew out of the genes separating the clusters. Lab assays then checked the model's key genes.
Patients with high scores lived better outcomes and answered immunotherapy more favorably, judging by checkpoint profiles and drug sensitivity patterns. Three genes stood out in validation: PD-L2, immunoglobulin J chain, and the CSF2 receptor beta chain. The authors present the signature as a dual-purpose tool, estimating both prognosis and likely benefit from immune treatment. They flag the three hub genes as candidates for future therapy research.
Catalog record
| CREATOR | Yang Wang, Ying Xie, Yiyi Ye, Youyang Shi, Feifei Li, Mengdie Zhu, Ciyi Hua, Yuan Xu, Rui Yang, Sheng Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51237 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |